Basement Membrane Pathology

Also written as Basement lamina.

The basement membrane (BM) is a thin extracellular matrix layer that supports epithelia and endothelium. Damage or thickening of BM underlies key lung and kidney diseases, altering gas exchange or filtration. Recognising BM involvement guides diagnosis and targeted therapy.

Definition and diagnosis

The BM is a specialised sheet of collagen IV, laminin, nidogen and proteoglycans that separates epithelial or endothelial cells from underlying connective tissue. Pathology is identified by histology (e.g., thickened BM on biopsy) or functional tests that reflect its role.

• Thin (≈0.1 µm) in normal lung alveoli and glomeruli
• Thickening or disruption seen in fibrosis, immune injury, infection

Severity and staging

Severity is graded by the extent of BM alteration on microscopy and by functional impact (e.g., diffusion capacity, proteinuria). In lung disease, a >30 % increase in BM thickness on biopsy correlates with moderate‑severe restriction; in kidney disease, BM thickening >300 nm predicts progressive nephropathy.

• Mild: focal changes, normal function
• Moderate: diffuse changes, mild functional loss
• Severe: extensive changes, marked functional impairment

Causes, most likely first

BM injury can be immune‑mediated, toxic, infectious or mechanical. In low‑resource settings, the most common triggers are:

• Anti‑GBM disease (Goodpasture’s) – auto‑antibodies to glomerular BM
• Post‑infectious glomerulonephritis – streptococcal, malaria, schistosomiasis
• Tuberculosis or HIV‑related interstitial lung disease – chronic inflammation
• Silica or asbestos exposure – occupational lung fibrosis
• Herbal nephrotoxins – aristolochic acid, traditional remedies

How it presents

Clinical clues reflect the organ involved. Lung BM disease presents with exertional dyspnoea, dry cough and low DLCO. Renal BM disease presents with haematuria, proteinuria and rising creatinine.

• Pulmonary: ↓ DLCO, normal spirometry early, hypoxaemia on exertion

Investigations

Use tests that answer whether the BM is structurally altered and whether function is impaired.

• Chest X‑ray / ultrasound: Is there interstitial infiltrate or pleural effusion? → Suggests lung BM fibrosis; if unavailable, rely on clinical DLCO.
• DLCO measurement: Is diffusion capacity reduced? → Low DLCO indicates thickened alveolar‑capillary BM.
• Renal biopsy (light microscopy, immunofluorescence): Is the glomerular BM thickened or immune‑deposited? → Confirms anti‑GBM, membranous nephropathy, or post‑infectious changes.
• Anti‑GBM antibody assay: Are circulating antibodies present? → Positive supports anti‑GBM disease; if unavailable, treat empirically if clinical picture fits.
• Urine microscopy & protein‑creatinine ratio: Is there haematuria with proteinuria? → Indicates intrinsic glomerular (BM) injury.

Red flags and complications

Unrecognised BM damage can rapidly progress to organ failure.

• Rapid rise in creatinine >30 % in 48 h (acute renal failure)
• Severe hypoxaemia (PaO₂ <60 mmHg) at rest
• Pulmonary haemorrhage in anti‑GBM disease

Management

Treat the underlying cause, then protect the organ and monitor function.

• Immune‑mediated BM disease: high‑dose IV methylprednisolone + cyclophosphamide; plasma exchange for anti‑GBM pulmonary‑renal syndrome.
• Infectious triggers: appropriate antimicrobial (e.g., penicillin for streptococcal GN, antimalarials for malaria‑related GN).
• Fibrotic lung BM disease: antifibrotics (pirfenidone, nintedanib) where available; otherwise smoking cessation, pulmonary rehab.
• Supportive renal care: ACE‑inhibitor/ARB to reduce proteinuria, careful fluid balance, dialysis if eGFR <15 mL/min/1.73 m².

Follow‑up and prevention

Regular functional testing detects progression early.

• Lung: repeat DLCO and spirometry every 6 months; vaccinate against influenza and pneumococcus.
• Kidney: urine protein/creatinine ratio and eGFR every 3 months; avoid nephrotoxic herbs and NSAIDs.

Often confused with

Conditions that affect similar structures but have different pathogenesis.

• Interstitial lung disease without BM involvement (e.g., sarcoidosis).
• Acute tubular necrosis – causes renal failure but spares BM.

Where results can mislead

Certain tests may be normal early despite significant BM injury.

• Normal chest X‑ray in early pulmonary BM fibrosis; rely on DLCO.
• Urine dipstick may miss low‑grade proteinuria; use protein‑creatinine ratio.

Questions an examiner may ask

• A 28‑year‑old man with haemoptysis and rapidly rising creatinine – what is the most likely diagnosis and immediate management? — Anti‑GBM disease; start high‑dose steroids, cyclophosphamide and plasma exchange.
• Why is DLCO more sensitive than chest X‑ray for early pulmonary basement membrane fibrosis? — DLCO detects diffusion impairment before radiographic changes appear.
• A child from a malaria‑endemic area presents with haematuria and proteinuria – which basement membrane pathology should you consider and why? — Post‑malaria glomerulonephritis; immune complexes deposit in the glomerular BM.
• What distinguishes anti‑GBM disease from membranous nephropathy on immunofluorescence? — Linear IgG along the BM in anti‑GBM versus granular deposits in membranous.
• In a patient with silicosis, how does basement membrane thickening cause exertional dyspnoea? — Thickened BM reduces diffusion capacity, limiting oxygen transfer during activity.
• When is plasma exchange indicated in basement membrane disease? — In pulmonary‑renal syndrome with anti‑GBM antibodies or severe pulmonary haemorrhage.
• How would you monitor treatment response in renal basement membrane disease without repeat biopsy? — Track protein‑creatinine ratio, urine sediment, and eGFR trends.
• What herbal remedy is known to cause basement membrane injury and how should you manage it? — Aristolochic acid; discontinue the herb, provide renal protective measures and consider dialysis if needed.

When to seek help

• Rapid renal function decline
• Severe hypoxaemia or respiratory distress
• Pulmonary haemorrhage or massive haematuria

Quick questions

Why does a low DLCO point to basement membrane disease?

DLCO measures gas diffusion across the alveolar‑capillary membrane; thickening of the BM impedes diffusion, lowering the value.

Can anti‑GBM disease affect both lung and kidney?

Yes; antibodies target the collagen IV in both glomerular and alveolar BM, causing pulmonary‑renal syndrome.

What if a renal biopsy cannot be performed?

Use clinical criteria (haematuria, proteinuria, rising creatinine) plus serology (anti‑GBM, complement) to start empiric therapy.